Search for tag: "impower110"

Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark Socinski

IMpower110 是第一個 PD-L1 藥物 (Tecentriq) 被證實在第一線單獨使用相對於化療能夠大幅提高病患整體存活期 (20.2 mo vs 13.1 mo)。 可以提供無法接受化療或是無法申請到健保的病患一個有效的治療選擇。

From  Yi Chang on March 25th, 2021 0 likes 15 plays 0  

Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark Socinski

IMpower110 是第一個 PD-L1 藥物 (Tecentriq) 被證實在第一線單獨使用相對於化療能夠大幅提高病患整體存活期 (20.2 mo vs 13.1 mo)。 可以提供無法接受化療或是無法申請到健保的病患一個有效的治療選擇。

From  Yi Chang on March 23rd, 2021 0 likes 11 plays 0  

Changing Landscape of PD-L1-high NSCLC treatments

Changing landscape for PD-L1-high NSCLC treatmentsSpeakers: Dr Ross Soo (Singapore, Moderator), Dr Mark Socinski (US, Speaker), Dr Roy Herbst (US, Speaker), Dr Yuh Min Chen (Taiwan,…

From  Kelda Tan on November 2nd, 2020 0 likes 139 plays 0  

Global Vision: Immunotherapy in NSCLC (26May2020)

Prof Zhou Caicun (Shanghai Pulmonary Hospital, Tongji University School of Medicine Shanghai), Dr Ross Soo (National University Cancer Institute, Singapore) and a panel of Chinese oncologists were…

From  Kelda Tan on June 1st, 2020 0 likes 23 plays 0